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Several scoring systems, based on traditional risk factors, are
available for the 10-year quantification of cardiovascular
(CV) risk for either coronary heart disease (CHD) or
cardiovascular disease (CVD) events. Assessing CV risk is
useful to identify patients requiring aggressive management
(i.e., high risk) or monitoring (i.e., low risk) or those at
intermediate risk. The last group presents treatment chal-
lenges and requires a case-by-case approach. Importantly,
available scoring systems should only be used in primary
prevention (i.e., before the occurrence of a CV event).
Patients with previous CV events are considered high risk
and should be managed accordingly.
See page 1025
It is well established that a substantial proportion of
CVD events is not accounted for by traditional risk factors
(1). Over the last 30 years, a better understanding of
atherosclerosis has led to the identification of novel, non-
traditional risk factors. For large-scale use, particularly in
the current economic climate, such nontraditional risk
factors should be: 1) easily and cheaply measurable; 2) related
to CV risk in a predictable fashion; and 3) potentially
modifiable by means of pharmacological and/or nonphar-
macological interventions. Therefore, by definition, nontra-
ditional CV risk factors must predict CVD events. How-
ever, their use in clinical practice adds little if they do not
substantially increase the capacity to predict CVD over and
above traditional risk factors.
Excessive plasma concentrations of the highly reactive
sulfur-containing amino acid homocysteine (Hcy) have
been long known to adversely affect vascular homeostasis
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that they have no relationships relevant to the contents of this paper to disclose.(2). Epidemiological studies have demonstrated a positive
and independent association between Hcy concentrations
and CVD events (2). The next logical step is determining
the clinical utility of measuring Hcy concentrations by
assessing both its predictive value, and most importantly, its
potential to assist in clinical decision making by reallocating
patients to either higher (i.e., aggressive management) or
lower (i.e., monitoring) risk categories.
In this issue of the Journal, Veeranna et al. (3) address this
topic by running post hoc analyses on the MESA (Multi-
Ethnic Study of Atherosclerosis) and NHANES III (Na-
tional Health and Nutrition Examination Survey III) trials.
The predictive power of Hcy was assessed by calculating the
area under the receiver operating characteristics curve (AU-
ROC) using the Framingham Risk Score (FRS) with and
without Hcy concentration. Improvement in risk classifica-
tion, equally important to risk prediction in quantifying the
usefulness of new markers, was measured via 2 relatively
new statistics, the net reclassification improvement index
(NRI) and the integrated discrimination improvement
(IDI) (4). The NRI examines the percentage of patients
who were better classified in terms of higher or lower risk
based upon their subsequent event status, following the
addition of the new variable to the risk prediction algorithm.
The IDI, another category-free index very similar in nature
to the AU-ROC or C-statistic, assesses the change in the
difference of the mean predicted probabilities of the out-
come between those with and without the disease; as such,
the IDI is not influenced by varying the selection of risk
score cut points.
The increases in AU-ROC observed by Veeranna et al.
(3) with the addition of Hcy level were of the order of 0.025,
indicating an additional 2.5% increase in the probability that
someone who had an event had a higher predicted risk than
someone who did not. This small increase is typical of
models that already contain at least a handful of strong
predictors. It is often hard to be convinced that such small
changes will translate into meaningful differences in patient
management, even if from a public health perspective,
changes of this magnitude might be meaningful. Despite
the small gains in predictive yield, much greater improve-
ments were obtained in reclassification, with approxi-
mately 20% of patients at intermediate risk being better
classified, with an overall downward reclassification of
risk among the nonevents (3). Mindful of the potential
for artificial enhancement of the NRI, which will vary
according to selection of the chosen FRS tertile cut
points, the authors reanalyzed the NRI using the recently
updated “category-free” NRI approach and confirmed
their findings (5).
This study provides a sound rationale for adding Hcy in
CVD risk assessment. An additional strength was the
adjustment for C-reactive protein and markers of renal
function, none of which affected either the predictive yield
of Hcy for CHD events or risk reclassification.
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need to be interpreted with caution for a number of reasons.
First, the FRS is not universally accepted because it assesses
CHD risk, rather than CVD risk, although modified
versions accounting for CVD events have been introduced
(6). Further studies are required to ascertain the role of Hcy
concentration in risk reclassification in cerebrovascular dis-
ease, peripheral arterial disease, and heart failure. Second,
the applicability of the FRS in populations outside the
United States is far from established. Whether the results
could be replicated using different scoring systems warrants
further investigation. Third, the use of the FRS in the
NHANES III cohort might be inappropriate because sev-
eral participants had a history of myocardial infarction or
cerebrovascular disease (7,8). As previously discussed, CV
risk scores should only be used in patients without previous
CV events (i.e., in primary prevention). Fourth, the NRI
statistic on its own does not indicate where the improve-
ments in classification occur (i.e., which tertile) and also to
whom (those who had the events or those who did not).
The modified risk engine was more successful in identifying
those who had events than those who did not with 19.4%
and 30.3% of patients who had events in MESA and
NHANES III, respectively, being correctly reclassified higher
compared with 3.0% and 5.7% of patients who did not have
events in the 2 respective cohorts being reclassified lower (3).
ncorrect reclassification was lower than correct reclassifica-
ion among patients with events (4.0% and 11.8% were
eclassified lower in MESA and NHANES III, respec-
ively) and similar to correct reclassification among patients
ithout events (5.4% and 5.7% were reclassified higher in
ESA and NHANES III, respectively). Overall, the NRI
as useful in better identifying patients who had a subse-
uent event, which is the primary objective of the risk
ngine, but did not better identify those without a subse-
uent event. In other studies, however, an improved NRI
ay arise from the opposite scenario; therefore, care needs
o be taken when NRI results are evaluated because similar
alues may arise for different reasons.
Where do we go from here? Notwithstanding the afore-
entioned issues, a possible step forward is using the results
f this study to determine the cost/benefit ratio of including
cy measurement in population screening programs. Com-
aring the results with other nontraditional CVD risk
arkers (e.g., C-reactive protein and coronary artery cal-
ium score) would be useful in the context of public health
nterventions. Moreover, it is known that Hcy is present in
arious forms, with different effects on vascular homeostasis
9). Analyzing specific Hcy forms might result in enhancedpredictive yield and risk reclassification and alter cost/
benefit ratios.
Finally, an important question remains: Because no large
randomized controlled trial has demonstrated any beneficial
effect of Hcy-lowering therapies on CV outcomes, should
we consider Hcy as a mere bystander? Veeranna et al. (3)
rightly argue that virtually all such trials have been con-
ducted in patients with advanced atherosclerosis (i.e., either
pre-existing CVD or very high risk). If Hcy is to be used as
a screening tool in primary prevention, it is imperative that
further trials are conducted in low- and intermediate-risk
patients without previous CVD. Only then can the real
value of measuring Hcy as a nontraditional CVD risk factor
or risk marker be quantified.
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